Hepatocellular Carcinoma Clinical Trials in Guangzhou, Guangdong
64 recruitingGuangzhou, Guangdong, China
Showing 1–20 of 64 trials
Recruiting
Phase 1
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines140 enrolled20 locationsNCT06427941
Recruiting
Phase 1Phase 2
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Hepatocellular CarcinomaSolid TumorsNon-small Cell Lung Cancer+1 more
3D Medicines (Sichuan) Co., Ltd.170 enrolled23 locationsNCT05024214
Recruiting
Phase 2
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Hepatocellular Carcinoma
Sun Yat-sen University55 enrolled1 locationNCT05751343
Recruiting
Phase 2Phase 3
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
Hepatocellular Carcinoma (HCC)
Zhujiang Hospital30 enrolled1 locationNCT06644937
Recruiting
Phase 2
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Hepatocellular Carcinoma (HCC)
Sun Yat-sen University30 enrolled1 locationNCT07192185
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
Hepatocellular Carcinoma (HCC)Microvascular Invasion (MVI)
Chinese Academy of Sciences400 enrolled19 locationsNCT07170345
Recruiting
Not Applicable
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Li Qiang286 enrolled1 locationNCT07070076
Recruiting
Phase 2
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University320 enrolled1 locationNCT06904183
Recruiting
Phase 2
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University130 enrolled1 locationNCT06397235
Recruiting
Not Applicable
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
Hepatocellular CarcinomaImmune-Mediated HepatitisLiver Failure
Third Affiliated Hospital, Sun Yat-Sen University60 enrolled1 locationNCT05484908
Recruiting
Phase 1
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
Hepatocellular CarcinomaHCCHepatitis B Virus Related Hepatocellular Carcinoma
SCG Cell Therapy Pte. Ltd.38 enrolled7 locationsNCT06617000
Recruiting
Not Applicable
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Hepatocellular CarcinomaAdjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University204 enrolled1 locationNCT06581315
Recruiting
Phase 2
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Hepatocellular CarcinomaSolid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University100 enrolled1 locationNCT04770207
Recruiting
Phase 2
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Hepatocellular CarcinomaSolid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University100 enrolled1 locationNCT04803318
Recruiting
Phase 1
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Hepatocellular CarcinomaLung CancerSolid Tumor
Second Affiliated Hospital of Guangzhou Medical University50 enrolled1 locationNCT04952272
Recruiting
Phase 1
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Hepatocellular CarcinomaImmunotherapySquamous Cell Lung Cancer+3 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled2 locationsNCT03198546
Recruiting
Phase 2
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University23 enrolled1 locationNCT06397222
Recruiting
Phase 1Phase 2
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University52 enrolled1 locationNCT05924997
Recruiting
Phase 3
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University427 enrolled1 locationNCT05608200
Recruiting
Phase 3
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University187 enrolled1 locationNCT05608213